Minera Alamos' "new" model for successful gold mining in the 21st century has a very retro flair to it.
TRYP THERAPEUTICS INC. Announces Amendment to Terms of Private Placement and Closing of $3,000,000 Second Tranche
Tryp Therapeutics closes the second tranche of its recently announced private placement for gross proceeds of CAD$3 million. Units are priced at CAD$0.15.
Psychedelic Drug Patenting: Still Only Scratching The Surface
Dozens of psychedelic drugs to research. Several "generations" of R&D ahead. To say that we're early in the game with psychedelic drug research is an understatement.
Kevin O’Leary Predicts These 3 Psychedelic Companies Will Merge, But Should They?
The "Shark Tank" star predicts three of the biggest psychedelic companies will merge into a mega corporation, but our resident Psychedelic Investor wonders: Should they?
Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder
Cybin announces a new clinical partner as it prepares for its Phase 1/2a clinical trial for CYB003.
Revitalist Reports Fourteen Months of Consecutive Monthly Visit Growth and a 466% Increase Year over Year for March 2022
Revitalist Lifestyle and Wellness announces 14th consecutive month of revenues growth and projects further growth across its network of 9 clinics.
Looking For The Perfect Inflation Hedge? Try This Company
Inflation is rapidly eroding our purchasing power and consuming our wealth. Here is a powerful antidote for investors.
Veterans Push to Persuade Lawmakers to Legalize Therapeutic Use of Psychedelics
New studies have indicated psilocybin could be useful in the treatment of everything from major depression to alcoholism.
Gold price attempts to take $2,000
Gold flirted with the $2,000 an ounce on Monday, led by safe-haven demand following a long weekend.
Magic mushrooms can lead to long-term improvements in depression, study finds
Magic mushroom's drug psilocybin can lead to long-term improvements in depression symptom severity, a small study has found.
Delic Labs Receives Health Canada 56 Exemption to Conduct Research on MDMA, LSD and Other Psychedelic Compounds
Delic Holdings announces receiving a Health Canada 56 Research Exemption to conduct research on various psychedelic drugs.
Mydecine Announces Reverse Stock-Split
Mydecine Innovations Group announces a share consolidation of 1 post-consolidation share for every 50 pre-consolidation shares.
